Pharma wants FDA’s IND reporting rule better aligned with ICH E2F
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesClinical TrialsComplianceNorth AmericaPharmaceuticalsProject managementRegulatory Intelligence/PolicyRegulatory NewsJoanne S. EglovitchBiologics/ biosimilars/ vaccinesClinical TrialsComplianceNorth AmericaPharmaceuticalsProject managementRegulatory Intelligence/Policy